Annexon Q3 2026 Earnings Date & Estimates

Annexon (NASDAQ:ANNX) is a clinical-stage biopharmaceutical company developing therapies for diseases driven by activation of the classical complement pathway, an immune-system mechanism involved in inflammation and tissue damage. The company’s approach is designed to selectively inhibit complement activity while preserving other parts of the immune response.

Annexon’s pipeline has included ANX005, an investigational monoclonal antibody that targets C1q, an initiating protein in the classical complement pathway. The company has studied ANX005 in neurological and autoimmune conditions, including Guillain-Barré syndrome. Annexon has also developed other complement-focused candidates, including ANX007, an investigational ophthalmic treatment designed to inhibit C1q activity in the eye, and ANX1502, an orally administered complement inhibitor.

Founded in 2011, Annexon is headquartered in South San Francisco, California, and focuses on developing medicines for patients with complement-mediated disorders. The company’s operations and clinical development activities are directed primarily toward advancing its investigational pipeline through clinical testing and regulatory evaluation. Douglas Love serves as the company’s chief executive officer.